GLASGOW, UNITED KINGDOM, Tuesday 7 September ľ SPIRIVA« (tiotropium) significantly reduced exacerbations and health resource utilization compared with placebo in patients with Chronic Obstructive Pulmonary Disease (COPD), according to data presented today at the annual European Respiratory Society meeting in Glasgow, Scotland.1,2 SPIRIVA« is a novel, inhaled, anticholinergic medication with 24-hour efficacy3 recommended for maintenance treatment of COPD. SPIRIVA« provides superior symptom relief and sustained improvement in lung function vs placebo so that patients with COPD can regain a better quality of life.3-5
COPD is a progressive respiratory disease that causes significant deterioration of lung function and chronic breathlessness, which can lead to severe disability.6 Chronic airflow limitation associated with COPD leads to excess air being trapped in the lungs after a person has fully exhaled. This condition, known as "air trapping", is a primary cause of breathlessness, which often restricts a patient's ability to perform daily activities such as walking up stairs or taking a shower.3,7 Currently, COPD is the fourth leading cause of death worldwide, claiming 2.75 million lives annually.8
"Current guidelines state that exacerbations, or acute worsening of disease symptoms, are a key target for COPD therapy because they severely impact quality of life, and are responsible for the majority of healthcare costs associated with treating COPD," said Professor Daniel Dusser, Head of Pneumology, H˘pital Cochin, Paris and principal study investigator.
In this one-year, placebo-controlled study involving 1,010 patients with COPD in 177 centres in France, SPIRIVA« was shown to significantly reduce the frequency of exacerbations compared to placebo (1.57 vs 2.41 per patient per year, -35%, p<0.01).1 The average number of exacerbation days was significantly lower with SPIRIVA« compared to placebo (21.1 vs 33.3 per patient per year, -37%, p<0.01), and the time to first exacerbation was also significantly prolonged (p<0.001).1
The reduction in exacerbations with SPIRIVA« was also associated with significantly lower health resource utilization.2 The following was observed compared to placebo:
- Significantly fewer unscheduled physician visits and phone calls to physicians per patient per year (-41%, p=0.0106 and -53%, p=0.0122 respectively)
- Hospitalizations were reduced per patient per year (-27%, p>0.05)
- Significantly fewer patients required additional respiratory medications for their exacerbations (30.5% vs 42.5%, p<0.0001)
- Significantly fewer courses of antibiotics (-34%, p=0.0005) and oral steroids (-24%, p=0.0083) were required per patient per year
- Significantly fewer patients required oxygen (2.6% vs 5.3%, p=0.027).
"The results of this study reinforce the effectiveness of SPIRIVA« as a maintenance therapy that significantly reduces COPD exacerbations, improving patient quality of life and reducing the related burden on health resources," Professor Daniel Dusser said.
In this study, exacerbations were defined as the onset of │1 clinical symptom in the past 24 hours (worsening of dyspnoea, cough or sputum production; appearance of purulent sputum; fever [>38░C] or appearance of new chest X-ray abnormality) requiring a new prescription, or an increase in the dose, of b2-agonists, antibiotics, corticosteroids or bronchodilators.
About SPIRIVA« (tiotropium)
SPIRIVA«, an inhaled anticholinergic medication, is the first inhaled treatment to provide significant and sustained improvements in lung function, with once-daily dosing. SPIRIVA« works through targeting of a dominant reversible mechanism of COPD ľ cholinergic bronchoconstriction. SPIRIVA« helps COPD patients breathe more easily by opening narrowed airways and helping to keep them open for 24 hours. According to treatment guidelines of the Global Initiative for Chronic Obstructive Lung Disease (GOLD), long-acting bronchodilators, including tiotropium, are a preferred treatment option for COPD maintenance therapy.
The SPIRIVA« clinical trials programme has recruited over 9,400 patients.9 SPIRIVA« has demonstrated significant and sustained bronchodilation (expansion of the lungs airways). 10-12 SPIRIVA« also demonstrated improvements in lung function (FEV1) vs ATROVENT« (ipratropium bromide inhalation aerosol), a current first-line therapy for COPD, which were maintained over one year.10,11 In addition, in one-year, placebo-controlled studies, patients treated with SPIRIVA« required fewer doses of rescue medications.12
In clinical trials, the most common adverse reaction reported with SPIRIVA« was dry mouth, which was usually mild and often resolved during treatment.10-12
Source: Eurekalert & othersLast reviewed: By John M. Grohol, Psy.D. on 21 Feb 2009
Published on PsychCentral.com. All rights reserved.
There are defeats more triumphant than victories.
~ Michel de Montaigne